TALS - New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics | Benzinga
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the biopharma industry and large hospital systems.
"I am exceptionally pleased with this strategic expansion of our CCS portfolio," said Christopher D. Hillyer, MD, President and Chief Executive Officer at NYBCe, "which now allows NYBCe to have in-house start-to-finish cell and gene therapy, and regenerative medicine, development and manufacturing capabilities. Our new facilities and expert teams are located within key geographies, with best-in-class GMP manufacturing, and a close-to-patient transportation network as well as leading academic medical centers, which will allow us to fast-track lifesaving therapies to hospital systems."
Both state-of-the-art facilities offer space for autologous ...